Narlaprevir

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Narlaprevir
Accession Number
DB14760
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
  • Narlaprevir
External IDs
SCH 900518 / SCH-900518 / SCH900518
Categories
UNII
2857LA2O07
CAS number
865466-24-6
Weight
Average: 707.97
Monoisotopic: 707.429170498
Chemical Formula
C36H61N5O7S
InChI Key
RICZEKWVNZFTNZ-IOBYQIKSSA-N
InChI
InChI=1S/C36H61N5O7S/c1-10-11-15-24(27(42)30(44)37-22-16-17-22)38-29(43)26-25-23(35(25,8)9)20-41(26)31(45)28(33(2,3)4)39-32(46)40-36(18-13-12-14-19-36)21-49(47,48)34(5,6)7/h22-26,28H,10-21H2,1-9H3,(H,37,44)(H,38,43)(H2,39,40,46)/t23-,24?,25-,26?,28?/m0/s1
IUPAC Name
N-cyclopropyl-3-{[(1R,5S)-3-{3,3-dimethyl-2-[({1-[(2-methylpropane-2-sulfonyl)methyl]cyclohexyl}carbamoyl)amino]butanoyl}-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2-yl]formamido}-2-oxoheptanamide
SMILES
CCCCC(NC(=O)C1[C@@H]2[C@H](CN1C(=O)C(NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
Wikipedia
Narlaprevir

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentHepatic Impairment1
2CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection1
2CompletedTreatmentChronic hepatitis C genotype 1b1
2, 3TerminatedOtherChronic Hepatitis C Virus (HCV) Infection / Hepacivirus1
3CompletedTreatmentHepatitis C Viral Infection1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00964 mg/mLALOGPS
logP3.44ALOGPS
logP3.5ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)12.32ChemAxon
pKa (Strongest Basic)-0.41ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area170.85 Å2ChemAxon
Rotatable Bond Count15ChemAxon
Refractivity186.29 m3·mol-1ChemAxon
Polarizability76.76 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on April 23, 2019 16:10 / Updated on November 02, 2019 03:26